PMID: 26320507Sep 1, 2015Paper

Epigenetic Regulation of miR-129-2 Leads to Overexpression of PDGFRa and FoxP1 in Glioma Cells

Asian Pacific Journal of Cancer Prevention : APJCP
Xiang-Yang TianMing Li

Abstract

miR-129-2 is frequently downregulated in multiple cancers. However, how it is silenced in cancers remains unclear. Here we investigated the expression profile and potential biological function of miR-129-2 in glioblastoma (GBM), the most common and lethal form of brain tumors in adults. We showed that miR-129-2 is lost in GBM patient specimens and cultured cell lines. miR-129-2 expression could be restored upon treatment with a histone deadetylase inhibitor (trichostatin A) but not a DNA methylation inhibitor (5-Aza-2'-deoxycytidine), and more profound effect was observed with the treatment of these two drugs in combination. Furthermore, forced expression of miR-129-2 repressed the expression of major oncogenic genes such as PDGFRa and Foxp1 in GBMs. Consistently, expression of miR-129-2 significantly inhibits GBM cell proliferation in vitro. These results reveal that miR-129-2 is epigenetically regulated and functions as a tumor suppressor gene in GBMs, suggesting it may serve as a potential therapeutic target for GBM treatment.

References

Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
Feb 23, 2010·Nature Cell Biology·Li MaRobert A Weinberg
Sep 2, 2011·Chinese Journal of Cancer·Kun-Wei LiuShi-Yuan Cheng
Dec 14, 2011·The Journal of Experimental Medicine·Ming LiFrank Furnari
Apr 10, 2015·Nature Reviews. Cancer·Frank B FurnariPaul S Mischel

❮ Previous
Next ❯

Citations

Jun 12, 2016·Briefings in Functional Genomics·Veronique G LeBlanc, Marco A Marra
May 4, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xin LuoYuan Yuan
Aug 23, 2018·Journal of Cellular and Molecular Medicine·Xinlin SunYiquan Ke
Feb 4, 2016·Asian Pacific Journal of Cancer Prevention : APJCP·Goot Heah KhorThong Kwai Lin
May 26, 2017·Cellular & Molecular Biology Letters·Emmanuel AmpofoMatthias W Laschke
Feb 12, 2021·Cellular & Molecular Biology Letters·Emmanuel OdameHongping Zhang
Feb 12, 2019·Seminars in Cancer Biology·Ammad Ahmad FarooqiGeorge A Calin
Sep 10, 2021·Journal of Gastrointestinal Cancer·Alireza Rezayi SoufianiAbdolreza Mehdinavaz Aghdam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.